Speaker Profile
M.D., CEO, Virchow Medical
Biography
Dr. Arrow co-founded Virchow Medical in 2023, whose mission is to allow hospitals to unlock critical molecular data for every cancer patient, enabling precision medicine to save more lives. The companys concordance studies are ongoing in six U.S. medical centers. He has served as its President and CEO since inception. From 2019 through 2022, Dr. Arrow was the CFO of Carlsmed, an orthopedic implant manufacturer that now trades on Nasdaq: CARL with a $400 million market cap. Previously, as the CFO of Arstasis, he helped that company raise $130 million in investment capital. He served on the Board of Paragonix Technologies, which in 2024 Getinge AG acquired for $477 million. Before joining these and other operating companies, Dr. Arrow had been the head of Medical Technology Equity Research at Lazard and Wedbush Morgan Securities. He is an inventor on eight issued U.S. patents.
Talk
Identifying More Patients Carrying Actionable Drug Targets
Around 50% of positive cancer diagnosis biopsies get genomic sequencing, yet most oncologists would prefer that they all do. In this talk, we'll show how residual cells on used biopsy needles are being collected to allow more patients to be sequenced, while generating new revenue for hospitals and labs.
Clinical Dx Showcase:
Virchow Medical, Inc.
Virchow Medical makes the Crow's Nest Biopsy Catchment System and Operates the Virchow Vault Liquid Companion Specimen Biorepository. We allow hospitals to unlock critical molecular data for every cancer patient, enabling precision medicine to save more lives without relying on the limited tissue sample, while generating testing volume for clinical labs and data for targeted therapy development.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
